{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:51:16Z","timestamp":1792785076806,"version":"4.5.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":144,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Natural Science Foundation of China","award":["82472706, 82403069, 82504077"],"award-info":[{"award-number":["82472706, 82403069, 82504077"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-026-01455-5","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:37:07Z","timestamp":1778733427000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["SPOCK1 acts as a negative regulator of ferroptosis in non-small cell lung cancer"],"prefix":"10.1038","volume":"10","author":[{"given":"Na","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ren","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Hu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Xin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Bin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"1455_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","volume":"10","author":"LEL Hendriks","year":"2024","unstructured":"Hendriks, L. E. L. et al. Non-small-cell lung cancer. Nat. Res. Dis. Prim. 10, 71 (2024).","journal-title":"Nat. Res. Dis. Prim."},{"key":"1455_CR2","doi-asserted-by":"crossref","unstructured":"Ren, F. et al. Liquid biopsy techniques and lung cancer: diagnosis, monitoring and evaluation. J. Exp. Clin. Cancer Res. 43, 96 (2024).","DOI":"10.1186\/s13046-024-03026-7"},{"key":"1455_CR3","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","volume":"19","author":"AJ Cooper","year":"2022","unstructured":"Cooper, A. J., Sequist, L. V. & Lin, J. J. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat. Rev. Clin. Oncol. 19, 499\u2013514 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1455_CR4","doi-asserted-by":"crossref","unstructured":"Pike, L. R. G. et al. Tyrosine kinase inhibitors with and without up-front stereotactic radiosurgery for brain metastases from EGFR and ALK oncogene-driven non-small cell lung cancer (TURBO-NSCLC). J. Clin. Oncol. 42, 3606\u20133617 (2024).","DOI":"10.1200\/JCO.23.02668"},{"key":"1455_CR5","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/S1470-2045(24)00379-6","volume":"25","author":"Y Zhao","year":"2024","unstructured":"Zhao, Y. et al. Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis. Lancet Oncol. 25, 1347\u20131356 (2024).","journal-title":"Lancet Oncol."},{"key":"1455_CR6","doi-asserted-by":"crossref","unstructured":"Qin, B. D. et al. Immunotherapy-based regimens for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy. J. Immunother. Cancer 12 (2024).","DOI":"10.1136\/jitc-2024-008818"},{"key":"1455_CR7","doi-asserted-by":"publisher","first-page":"C688","DOI":"10.1152\/ajpcell.00033.2022","volume":"322","author":"L V\u00e1ncza","year":"2022","unstructured":"V\u00e1ncza, L., T\u00e1trai, P., Reszegi, A., Baghy, K. & Kovalszky, I. SPOCK1 with unexpected function. The start of a new career. Am. J. Physiol. Cell Physiol. 322, C688\u2013c693 (2022).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"1455_CR8","doi-asserted-by":"crossref","unstructured":"Xiao, M., Xue, J. & Jin, E. SPOCK: master regulator of malignant tumors (Review). Mol. Med. Rep. 30 (2024).","DOI":"10.3892\/mmr.2024.13355"},{"key":"1455_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-014-0276-y","volume":"14","author":"YJ Shu","year":"2015","unstructured":"Shu, Y. J. et al. SPOCK1 as a potential cancer prognostic marker promotes the proliferation and metastasis of gallbladder cancer cells by activating the PI3K\/AKT pathway. Mol. Cancer 14, 12 (2015).","journal-title":"Mol. Cancer"},{"key":"1455_CR10","doi-asserted-by":"crossref","unstructured":"Chien, M. H. et al. Targeting the SPOCK1-snail\/slug axis-mediated epithelial-to-mesenchymal transition by apigenin contributes to repression of prostate cancer metastasis. J. Exp. Clin. Cancer Res. 38, 246 (2019).","DOI":"10.1186\/s13046-019-1247-3"},{"key":"1455_CR11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/cpr.12241","volume":"49","author":"F Yu","year":"2016","unstructured":"Yu, F. et al. SPOCK1 is upregulated in recurrent glioblastoma and contributes to metastasis and Temozolomide resistance. Cell Prolif. 49, 195\u2013206 (2016).","journal-title":"Cell Prolif."},{"key":"1455_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-021-00376-1","volume":"11","author":"R Babaei-Jadidi","year":"2022","unstructured":"Babaei-Jadidi, R. et al. Anti-miR-135\/SPOCK1 axis antagonizes the influence of metabolism on drug response in intestinal\/colon tumour organoids. Oncogenesis 11, 4 (2022).","journal-title":"Oncogenesis"},{"key":"1455_CR13","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41388-024-03220-z","volume":"44","author":"H Li","year":"2025","unstructured":"Li, H. et al. RBM15 facilitates osimertinib resistance of lung adenocarcinoma through m6A-dependent epigenetic silencing of SPOCK1. Oncogene 44, 307\u2013321 (2025).","journal-title":"Oncogene"},{"key":"1455_CR14","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang, X., Stockwell, B. R. & Conrad, M. Ferroptosis: mechanisms, biology and role in disease. Nat. Rev. Mol. Cell Biol. 22, 266\u2013282 (2021).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1455_CR15","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon, S. J. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060\u20131072 (2012).","journal-title":"Cell"},{"key":"1455_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39401-9","volume":"14","author":"Y Yan","year":"2023","unstructured":"Yan, Y. et al. SLC7A11 expression level dictates differential responses to oxidative stress in cancer cells. Nat. Commun. 14, 3673 (2023).","journal-title":"Nat. Commun."},{"key":"1455_CR17","doi-asserted-by":"crossref","unstructured":"Zhang, W. et al. RBMS1 regulates lung cancer ferroptosis through translational control of SLC7A11. J. Clin. Invest. 131 (2021).","DOI":"10.1172\/JCI152067"},{"key":"1455_CR18","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","volume":"156","author":"WS Yang","year":"2014","unstructured":"Yang, W. S. et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317\u2013331 (2014).","journal-title":"Cell"},{"key":"1455_CR19","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.immuni.2017.03.022","volume":"46","author":"RI Klein Geltink","year":"2017","unstructured":"Klein Geltink, R. I., O\u2019Sullivan, D. & Pearce, E. L. Caught in the cROSsfire: GSH controls T cell metabolic reprogramming. Immunity 46, 525\u2013527 (2017).","journal-title":"Immunity"},{"key":"1455_CR20","doi-asserted-by":"publisher","first-page":"121110","DOI":"10.1016\/j.biomaterials.2021.121110","volume":"277","author":"B Niu","year":"2021","unstructured":"Niu, B. et al. Application of glutathione depletion in cancer therapy: enhanced ROS-based therapy, ferroptosis, and chemotherapy. Biomaterials 277, 121110 (2021).","journal-title":"Biomaterials"},{"key":"1455_CR21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ccell.2018.12.009","volume":"35","author":"H Ogiwara","year":"2019","unstructured":"Ogiwara, H. et al. Targeting the vulnerability of glutathione metabolism in ARID1A-deficient cancers. Cancer Cell 35, 177\u2013190.e178 (2019).","journal-title":"Cancer Cell"},{"key":"1455_CR22","doi-asserted-by":"publisher","first-page":"8039","DOI":"10.1021\/acsnano.1c00498","volume":"15","author":"X Cheng","year":"2021","unstructured":"Cheng, X., Xu, H. D., Ran, H. H., Liang, G. & Wu, F. G. Glutathione-depleting nanomedicines for synergistic cancer therapy. ACS Nano 15, 8039\u20138068 (2021).","journal-title":"ACS Nano"},{"key":"1455_CR23","doi-asserted-by":"publisher","first-page":"8535","DOI":"10.7150\/thno.61452","volume":"11","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. Neuronal-driven glioma growth requires G\u03b1i1 and G\u03b1i3. Theranostics 11, 8535\u20138549 (2021).","journal-title":"Theranostics"},{"key":"1455_CR24","doi-asserted-by":"publisher","first-page":"4599","DOI":"10.7150\/thno.55655","volume":"11","author":"YY Gao","year":"2021","unstructured":"Gao, Y. Y. et al. The histone acetyltransferase HBO1 functions as a novel oncogenic gene in osteosarcoma. Theranostics 11, 4599\u20134615 (2021).","journal-title":"Theranostics"},{"key":"1455_CR25","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abn6928","volume":"8","author":"J Yao","year":"2022","unstructured":"Yao, J. et al. The requirement of phosphoenolpyruvate carboxykinase 1 for angiogenesis in vitro and in vivo. Sci. Adv. 8, eabn6928 (2022).","journal-title":"Sci. Adv."},{"key":"1455_CR26","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41419-025-07410-9","volume":"16","author":"XR Zhu","year":"2025","unstructured":"Zhu, X. R. et al. A novel identified epithelial ligand-receptor-associated gene signature highlights POPDC3 as a potential therapy target for non-small cell lung cancer. Cell Death Dis. 16, 114 (2025).","journal-title":"Cell Death Dis."},{"key":"1455_CR27","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1038\/s41388-018-0184-5","volume":"37","author":"YY Liu","year":"2018","unstructured":"Liu, Y. Y. et al. microRNA-200a downregulation in human glioma leads to G\u03b1i1 over-expression, Akt activation, and cell proliferation. Oncogene 37, 2890\u20132902 (2018).","journal-title":"Oncogene"},{"key":"1455_CR28","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/s41419-021-04201-w","volume":"12","author":"XR Zhu","year":"2021","unstructured":"Zhu, X. R. et al. Identification of phosphoenolpyruvate carboxykinase 1 as a potential therapeutic target for pancreatic cancer. Cell Death Dis. 12, 918 (2021).","journal-title":"Cell Death Dis."},{"key":"1455_CR29","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41419-024-07079-6","volume":"15","author":"JZ Jiang","year":"2024","unstructured":"Jiang, J. Z. et al. Identification of G\u03b1i3 as a promising molecular oncotarget of pancreatic cancer. Cell Death Dis. 15, 699 (2024).","journal-title":"Cell Death Dis."},{"key":"1455_CR30","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41419-023-05684-5","volume":"14","author":"SQ Peng","year":"2023","unstructured":"Peng, S. Q. et al. Identification of matrix-remodeling associated 5 as a possible molecular oncotarget of pancreatic cancer. Cell Death Dis. 14, 157 (2023).","journal-title":"Cell Death Dis."},{"key":"1455_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38196-z","volume":"14","author":"J Shi","year":"2023","unstructured":"Shi, J. et al. Genome-wide association study of lung adenocarcinoma in East Asia and comparison with a European population. Nat. Commun. 14, 3043 (2023).","journal-title":"Nat. Commun."},{"key":"1455_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/pcmedi\/pbad002","volume":"6","author":"Z Tian","year":"2023","unstructured":"Tian, Z. et al. CAS Array: design and assessment of a genotyping array for Chinese biobanking. Precis. Clin. Med. 6, pbad002 (2023).","journal-title":"Precis. Clin. Med."},{"key":"1455_CR33","doi-asserted-by":"crossref","unstructured":"Xie, T. et al. Cohort profile: kunshan aging research with E-health (KARE). Int. J. Epidemiol. 54 (2025).","DOI":"10.1093\/ije\/dyaf041"},{"key":"1455_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-023-04203-7","volume":"23","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. Association of mitochondrial DNA copy number with chronic kidney disease in older adults. BMC Geriatr. 23, 514 (2023).","journal-title":"BMC Geriatr."},{"key":"1455_CR35","doi-asserted-by":"publisher","first-page":"D971","DOI":"10.1093\/nar\/gkx861","volume":"46","author":"J Gong","year":"2018","unstructured":"Gong, J. et al. PancanQTL: systematic identification of cis-eQTLs and trans-eQTLs in 33 cancer types. Nucleic Acids Res. 46, D971\u2013d976 (2018).","journal-title":"Nucleic Acids Res."},{"key":"1455_CR36","doi-asserted-by":"publisher","first-page":"188462","DOI":"10.1016\/j.bbcan.2020.188462","volume":"1875","author":"CM Dowling","year":"2021","unstructured":"Dowling, C. M., Zhang, H., Chonghaile, T. N. & Wong, K. K. Shining a light on metabolic vulnerabilities in non-small cell lung cancer. Biochim. Biophys. Acta Rev. Cancer 1875, 188462 (2021).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"1455_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-022-00412-1","volume":"10","author":"L Lv","year":"2022","unstructured":"Lv, L., Huang, R. H., Li, J., Xu, J. & Gao, W. Impact of NSCLC metabolic remodeling on immunotherapy effectiveness. Biomark. Res. 10, 66 (2022).","journal-title":"Biomark. Res."},{"key":"1455_CR38","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s13167-024-00357-5","volume":"15","author":"O Bajinka","year":"2024","unstructured":"Bajinka, O., Ouedraogo, S. Y., Golubnitschaja, O., Li, N. & Zhan, X. Energy metabolism as the hub of advanced non-small cell lung cancer management: a comprehensive view in the framework of predictive, preventive, and personalized medicine. EPMA J. 15, 289\u2013319 (2024).","journal-title":"EPMA J."},{"key":"1455_CR39","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1016\/j.cmet.2021.09.002","volume":"33","author":"SM Morrissey","year":"2021","unstructured":"Morrissey, S. M. et al. Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic dominant metabolic reprogramming. Cell Metab. 33, 2040\u20132058.e2010 (2021).","journal-title":"Cell Metab."},{"key":"1455_CR40","doi-asserted-by":"publisher","first-page":"108183","DOI":"10.1016\/j.compbiomed.2024.108183","volume":"171","author":"B Hao","year":"2024","unstructured":"Hao, B. et al. Identification of SLC2A1 as a predictive biomarker for survival and response to immunotherapy in lung squamous cell carcinoma. Comput. Biol. Med. 171, 108183 (2024).","journal-title":"Comput. Biol. Med."},{"key":"1455_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38148-7","volume":"14","author":"RC Slieker","year":"2023","unstructured":"Slieker, R. C. et al. Identification of biomarkers for glycaemic deterioration in type 2 diabetes. Nat. Commun. 14, 2533 (2023).","journal-title":"Nat. Commun."},{"key":"1455_CR42","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.bbrc.2020.09.129","volume":"533","author":"R Alshargabi","year":"2020","unstructured":"Alshargabi, R. et al. SPOCK1 induces adipose tissue maturation: New insights into the function of SPOCK1 in metabolism. Biochem. Biophys. Res. Commun. 533, 1076\u20131082 (2020).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1455_CR43","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41419-023-06045-y","volume":"14","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. The diversified role of mitochondria in ferroptosis in cancer. Cell Death Dis. 14, 519 (2023).","journal-title":"Cell Death Dis."},{"key":"1455_CR44","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41392-024-01769-5","volume":"9","author":"Q Zhou","year":"2024","unstructured":"Zhou, Q. et al. Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies. Signal Transduct. Target. Ther. 9, 55 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1455_CR45","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41392-022-00872-9","volume":"7","author":"Y Jin","year":"2022","unstructured":"Jin, Y. et al. Targeting polarized phenotype of microglia via IL6\/JAK2\/STAT3 signaling to reduce NSCLC brain metastasis. Signal Transduct. Target. Ther. 7, 52 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1455_CR46","doi-asserted-by":"crossref","unstructured":"Liang, L. et al. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2\/STAT3\/VEGFA signaling in non-small cell lung cancer cells. J. Exp. Clin. Cancer Res. 38, 71 (2019)","DOI":"10.1186\/s13046-019-1093-3"},{"key":"1455_CR47","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/s41419-022-04890-x","volume":"13","author":"LN Wang","year":"2022","unstructured":"Wang, L. N. et al. TGF-\u03b21\/SH2B3 axis regulates anoikis resistance and EMT of lung cancer cells by modulating JAK2\/STAT3 and SHP2\/Grb2 signaling pathways. Cell Death Dis. 13, 472 (2022).","journal-title":"Cell Death Dis."},{"key":"1455_CR48","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.devcel.2023.06.005","volume":"58","author":"NM O\u2019Brown","year":"2023","unstructured":"O\u2019Brown, N. M. et al. The secreted neuronal signal Spock1 promotes blood-brain barrier development. Dev. Cell 58, 1534\u20131547.e1536 (2023).","journal-title":"Dev. Cell"},{"key":"1455_CR49","first-page":"3127","volume":"10","author":"Z Ye","year":"2020","unstructured":"Ye, Z. et al. SPOCK1: a multi-domain proteoglycan at the crossroads of extracellular matrix remodeling and cancer development. Am. J. Cancer Res. 10, 3127\u20133137 (2020).","journal-title":"Am. J. Cancer Res."},{"key":"1455_CR50","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41580-022-00531-5","volume":"24","author":"P Kanchanawong","year":"2023","unstructured":"Kanchanawong, P. & Calderwood, D. A. Organization, dynamics and mechanoregulation of integrin-mediated cell-ECM adhesions. Nat. Rev. Mol. Cell Biol. 24, 142\u2013161 (2023).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1455_CR51","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41580-024-00777-1","volume":"26","author":"MR Chastney","year":"2025","unstructured":"Chastney, M. R., Kaivola, J., Lepp\u00e4nen, V. M. & Ivaska, J. The role and regulation of integrins in cell migration and invasion. Nat. Rev. Mol.Cell Biol. 26, 147\u2013167 (2025).","journal-title":"Nat. Rev. Mol.Cell Biol."},{"key":"1455_CR52","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41374-020-0425-4","volume":"100","author":"Z Du","year":"2020","unstructured":"Du, Z. et al. SPOCK1 overexpression induced by platelet-derived growth factor-BB promotes hepatic stellate cell activation and liver fibrosis through the integrin \u03b15\u03b21\/PI3K\/Akt signaling pathway. Lab. Invest. 100, 1042\u20131056 (2020).","journal-title":"Lab. Invest."},{"key":"1455_CR53","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1038\/onc.2010.532","volume":"30","author":"AK Mitra","year":"2011","unstructured":"Mitra, A. K. et al. Ligand-independent activation of c-Met by fibronectin and \u03b1(5)\u03b2(1)-integrin regulates ovarian cancer invasion and metastasis. Oncogene 30, 1566\u20131576 (2011).","journal-title":"Oncogene"},{"key":"1455_CR54","doi-asserted-by":"publisher","first-page":"218150","DOI":"10.1016\/j.canlet.2025.218150","volume":"638","author":"Z Chen","year":"2026","unstructured":"Chen, Z. et al. ANGPTL3 promotes colorectal carcinoma progression and metastasis through regulating COL1A2 transcription via interacting with integrin \u03b1V\u03b23. Cancer Lett. 638, 218150 (2026).","journal-title":"Cancer Lett."},{"key":"1455_CR55","doi-asserted-by":"publisher","first-page":"106654","DOI":"10.1016\/j.phrs.2023.106654","volume":"188","author":"Q Wu","year":"2023","unstructured":"Wu, Q. et al. Inhibition of bladder cancer growth with homoharringtonine by inactivating integrin \u03b15\/\u03b21-FAK\/Src axis: a novel strategy for drug application. Pharmacol. Res. 188, 106654 (2023).","journal-title":"Pharmacol. Res."},{"key":"1455_CR56","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1158\/0008-5472.CAN-15-2973","volume":"76","author":"X Yang","year":"2016","unstructured":"Yang, X. et al. FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling. Cancer Res. 76, 4124\u20134135 (2016).","journal-title":"Cancer Res."},{"key":"1455_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-016-0561-z","volume":"15","author":"YM Pan","year":"2016","unstructured":"Pan, Y. M. et al. STAT3 signaling drives EZH2 transcriptional activation and mediates poor prognosis in gastric cancer. Mol. Cancer 15, 79 (2016).","journal-title":"Mol. Cancer"},{"key":"1455_CR58","doi-asserted-by":"publisher","first-page":"102317","DOI":"10.1016\/j.redox.2022.102317","volume":"52","author":"S Ouyang","year":"2022","unstructured":"Ouyang, S. et al. Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer. Redox Biol. 52, 102317 (2022).","journal-title":"Redox Biol."},{"key":"1455_CR59","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1038\/s41401-024-01258-z","volume":"45","author":"JQ Lai","year":"2024","unstructured":"Lai, J. Q. et al. Baicalein triggers ferroptosis in colorectal cancer cells via blocking the JAK2\/STAT3\/GPX4 axis. Acta Pharmacol. Sin. 45, 1715\u20131726 (2024).","journal-title":"Acta Pharmacol. Sin."},{"key":"1455_CR60","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41418-019-0380-z","volume":"27","author":"L Wang","year":"2020","unstructured":"Wang, L. et al. ATF3 promotes erastin-induced ferroptosis by suppressing system Xc(). Cell Death Differ. 27, 662\u2013675 (2020).","journal-title":"Cell Death Differ."},{"key":"1455_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1062-7","volume":"18","author":"A Lin","year":"2019","unstructured":"Lin, A., Wei, T., Meng, H., Luo, P. & Zhang, J. Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. Mol. Cancer 18, 139 (2019).","journal-title":"Mol. Cancer"},{"key":"1455_CR62","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.immuni.2018.09.020","volume":"49","author":"G Mollaoglu","year":"2018","unstructured":"Mollaoglu, G. et al. The lineage-defining transcription factors SOX2 and NKX2-1 determine lung cancer cell fate and shape the tumor immune microenvironment. Immunity 49, 764\u2013779.e769 (2018).","journal-title":"Immunity"},{"key":"1455_CR63","doi-asserted-by":"crossref","unstructured":"Cascone, T. et al. Tumor immunology and immunotherapy of non-small-cell lung cancer. Cold Spring Harb. Perspect. Med. 12 (2022)","DOI":"10.1101\/cshperspect.a037895"},{"key":"1455_CR64","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1016\/j.ccell.2024.10.010","volume":"42","author":"H Lin","year":"2024","unstructured":"Lin, H. et al. Itaconate transporter SLC13A3 impairs tumor immunity via endowing ferroptosis resistance. Cancer Cell 42, 2032\u20132044.e2036 (2024).","journal-title":"Cancer Cell"},{"key":"1455_CR65","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1016\/j.immuni.2024.08.003","volume":"57","author":"Y Ping","year":"2024","unstructured":"Ping, Y. et al. PD-1 signaling limits expression of phospholipid phosphatase 1 and promotes intratumoral CD8(+) T cell ferroptosis. Immunity 57, 2122\u20132139.e2129 (2024).","journal-title":"Immunity"},{"key":"1455_CR66","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13045-017-0399-x","volume":"10","author":"N Perurena","year":"2017","unstructured":"Perurena, N. et al. EPCR promotes breast cancer progression by altering SPOCK1\/testican 1-mediated 3D growth. J. Hematol. Oncol. 10, 23 (2017).","journal-title":"J. Hematol. Oncol."},{"key":"1455_CR67","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nrc3803","volume":"14","author":"SS Sabharwal","year":"2014","unstructured":"Sabharwal, S. S. & Schumacker, P. T. Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles\u2019 heel? Nat. Rev. Cancer 14, 709\u2013721 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"1455_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2018.11.001","volume":"41","author":"Q Cui","year":"2018","unstructured":"Cui, Q. et al. Modulating ROS overcome multidrug resistance cancer. Drug Resist. Updat. 41, 1\u201325 (2018).","journal-title":"Drug Resist. Updat."},{"key":"1455_CR69","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.tibs.2019.01.001","volume":"44","author":"K Wang","year":"2019","unstructured":"Wang, K. et al. Targeting metabolic-redox circuits for cancer therapy. Trends Biochem. Sci. 44, 401\u2013414 (2019).","journal-title":"Trends Biochem. Sci."},{"key":"1455_CR70","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s11658-023-00449-6","volume":"28","author":"L Wang","year":"2023","unstructured":"Wang, L. et al. Melatonin and erastin emerge synergistic anti-tumor effects on oral squamous cell carcinoma by inducing apoptosis, ferroptosis, and inhibiting autophagy through promoting ROS. Cell. Mol. Biol. Lett. 28, 36 (2023).","journal-title":"Cell. Mol. Biol. Lett."},{"key":"1455_CR71","doi-asserted-by":"crossref","unstructured":"Yang, H. et al. The role of cellular reactive oxygen species in cancer chemotherapy. J. Exp. Clin. Cancer Res. 37, 266 (2018).","DOI":"10.1186\/s13046-018-0909-x"},{"key":"1455_CR72","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/s41419-019-2064-5","volume":"10","author":"E Park","year":"2019","unstructured":"Park, E. & Chung, S. W. ROS-mediated autophagy increases intracellular iron levels and ferroptosis by ferritin and transferrin receptor regulation. Cell Death Dis. 10, 822 (2019).","journal-title":"Cell Death Dis."},{"key":"1455_CR73","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/s41419-023-05859-0","volume":"14","author":"S Zhang","year":"2023","unstructured":"Zhang, S. et al. Chemotherapy impairs ovarian function through excessive ROS-induced ferroptosis. Cell Death Dis. 14, 340 (2023).","journal-title":"Cell Death Dis."},{"key":"1455_CR74","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/nrc3818","volume":"14","author":"H Yu","year":"2014","unstructured":"Yu, H., Lee, H., Herrmann, A., Buettner, R. & Jove, R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat. Rev. Cancer 14, 736\u2013746 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"1455_CR75","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01258-7","volume":"19","author":"S Zou","year":"2020","unstructured":"Zou, S. et al. Targeting STAT3 in cancer immunotherapy. Mol. cancer 19, 145 (2020).","journal-title":"Mol. cancer"},{"key":"1455_CR76","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3724\/abbs.2023068","volume":"55","author":"Y Wu","year":"2023","unstructured":"Wu, Y. et al. Ginsenoside Rh3 induces pyroptosis and ferroptosis through the Stat3\/p53\/NRF2 axis in colorectal cancer cells. Acta Biochim. Biophys. Sin. 55, 587\u2013600 (2023).","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"1455_CR77","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s13577-022-00754-w","volume":"35","author":"J Ji","year":"2022","unstructured":"Ji, J., Li, H., Wang, W., Yuan, B. & Shen, T. ARPC1A is regulated by STAT3 to inhibit ferroptosis and promote prostate cancer progression. Hum. Cell 35, 1591\u20131601 (2022).","journal-title":"Hum. Cell"},{"key":"1455_CR78","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41571-025-01011-3","volume":"22","author":"SM Ernst","year":"2025","unstructured":"Ernst, S. M. et al. Utilizing ctDNA to discover mechanisms of resistance to targeted therapies in patients with metastatic NSCLC: towards more informative trials. Nat. Rev. Clin. Oncol. 22, 371\u2013378 (2025).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1455_CR79","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","volume":"404","author":"ML Meyer","year":"2024","unstructured":"Meyer, M. L. et al. New promises and challenges in the treatment of advanced non-small-cell lung cancer. Lancet 404, 803\u2013822 (2024).","journal-title":"Lancet"},{"key":"1455_CR80","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40259-024-00700-2","volume":"39","author":"A Mariniello","year":"2025","unstructured":"Mariniello, A. et al. Primary and acquired resistance to immunotherapy with checkpoint inhibitors in nsclc: from bedside to bench and back. BioDrugs 39, 215\u2013235 (2025).","journal-title":"BioDrugs"},{"key":"1455_CR81","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01530-y","volume":"21","author":"C Zhang","year":"2022","unstructured":"Zhang, C., Liu, X., Jin, S., Chen, Y. & Guo, R. Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. Mol. Cancer 21, 47 (2022).","journal-title":"Mol. Cancer"},{"key":"1455_CR82","doi-asserted-by":"crossref","unstructured":"Wang, Y. et al. Overcoming cancer chemotherapy resistance by the induction of ferroptosis. Drug Resist. Updat. 66, 100916 (2023)","DOI":"10.1016\/j.drup.2022.100916"},{"key":"1455_CR83","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1158\/0008-5472.CAN-20-3477","volume":"81","author":"A Ghoochani","year":"2021","unstructured":"Ghoochani, A. et al. Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer. Cancer Res. 81, 1583\u20131594 (2021).","journal-title":"Cancer Res."},{"key":"1455_CR84","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41392-023-01606-1","volume":"8","author":"S Sun","year":"2023","unstructured":"Sun, S., Shen, J., Jiang, J., Wang, F. & Min, J. Targeting ferroptosis opens new avenues for the development of novel therapeutics. Signal Transduct. Target. Ther. 8, 372 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1455_CR85","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/cac2.12284","volume":"42","author":"M Huang","year":"2022","unstructured":"Huang, M. et al. HSF1 facilitates the multistep process of lymphatic metastasis in bladder cancer via a novel PRMT5-WDR5-dependent transcriptional program. Cancer Commun. 42, 447\u2013470 (2022).","journal-title":"Cancer Commun."},{"key":"1455_CR86","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.7150\/thno.82431","volume":"13","author":"Y Chin","year":"2023","unstructured":"Chin, Y. et al. Targeting HSF1 for cancer treatment: mechanisms and inhibitor development. Theranostics 13, 2281\u20132300 (2023).","journal-title":"Theranostics"},{"key":"1455_CR87","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abo1123","volume":"8","author":"M Pariollaud","year":"2022","unstructured":"Pariollaud, M. et al. Circadian disruption enhances HSF1 signaling and tumorigenesis in Kras-driven lung cancer. Sci. Adv. 8, eabo1123 (2022).","journal-title":"Sci. Adv."},{"key":"1455_CR88","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02477-6","volume":"24","author":"YT Liu","year":"2025","unstructured":"Liu, Y. T. et al. Turning cold tumors into hot tumors to ignite immunotherapy. Mol. Cancer 24, 254 (2025).","journal-title":"Mol. Cancer"},{"key":"1455_CR89","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon, J. & Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov. 18, 197\u2013218 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1455_CR90","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202310308","volume":"12","author":"T Yu","year":"2025","unstructured":"Yu, T. et al. Inhibition of glutamate-to-glutathione flux promotes tumor antigen presentation in colorectal cancer cells. Adv. Sci. 12, e2310308 (2025).","journal-title":"Adv. Sci."},{"key":"1455_CR91","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.cmet.2020.03.004","volume":"31","author":"H Kurniawan","year":"2020","unstructured":"Kurniawan, H. et al. Glutathione restricts serine metabolism to preserve regulatory T cell function. Cell Metab. 31, 920\u2013936.e927 (2020).","journal-title":"Cell Metab."},{"key":"1455_CR92","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1016\/j.immuni.2025.08.008","volume":"58","author":"DB Rivadeneira","year":"2025","unstructured":"Rivadeneira, D. B. et al. Oxidative-stress-induced telomere instability drives T cell dysfunction in cancer. Immunity 58, 2524\u20132540.e2525 (2025).","journal-title":"Immunity"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01455-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01455-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01455-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:02:31Z","timestamp":1791266551000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01455-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":92,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1455"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01455-5","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"370"}}